Skip to main content
. 2021 Nov 3;92(5):e2021365. doi: 10.23750/abm.v92i5.11417

Table 2.

Comorbidities in general study population, in survived/deceased and non-ICU/ICU patient subgroups.

n (%)
General population (n=231) Non-ICU (n=157) ICU (n=74) Survived (n=101) Deceased (n=130) p*
Hypertension 137 59.3% 103 65.6% 34 45.9% 47 46.5% 90 69.2% <0.001
Diabetes 65 28.1% 55 35% 10 13.5% 28 27.7% 37 28.5% 0.901
Cardiac disease 40 17.3% 34 21.6% 6 8.1% 10 9.9% 30 23.1% 0.001
COPD 24 10.4% 19 12.1% 5 6.8% 16 15.8% 8 6.2% 0.017
Other respiratory diseases 31 13.4% 24 15.2% 7 9.4% 19 18.8% 12 9.2% OSAS: 0.865
Asthma:
0.276
CKD 8 3.5% 7 4.5% 1 1.4% 1 1% 7 5.4% 0.070
Liver disease 14 6.1% 10 6.3% 4 5.6% 5 5.0% 9 6.9% 0.533
Vasculopathy 9 3.9% 7 4.5% 2 2.8% 3 3.0% 6 4.6% 0.522
Malignancy 13 5.6% 8 5.1% 5 6.7% 3 3.0% 10 7.7% 0.122
DVT/PE 6 2.6% 5 3.2% 1 1.4% 0 0.0% 6 4.6% 0.029
Stroke/ TIA 6 2.6% 3 1.9% 3 4.2% 2 2.0% 4 3.1% 0.629

n, number; ICU, intensive care unit; Cardiac disease: structural, valvular or arrhythmic; COPD, chronic obstructive pulmonary disease; Other respiratory disease, asthma and OSAS (Obstructive Sleep Apnea Syndrome); CKD, chronic kidney disease; DVT, deep vein thrombosis; PE, pulmonary embolism; TIA, transient ischemic attack. *p value has been calculated for survived and deceased patients.